Bambusa Therapeutics Inc. (BBTX)
NASDAQ: BBTXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
BBTX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $815.08M
- EPS (TTM)
- -$1.73
- Dividend yield
- None
- 52-week range
- 13.60 – 17.65
- Day range
- 15.21 – 16.69
- Volume / Avg
- 137.67K / 359.41K
- Beta
- —
- Shares outstanding
- 50.94M
52-week range
BBTX stock today
Shares of Bambusa Therapeutics (BBTX) finished higher on Nov 20 at $16.00, a gain of 2.89% or $0.45 per share, versus the S&P 500's 3.70% decline. Trading was light, with 137.67K shares changing hands, about 38% of the average daily volume. At this level, BBTX sits in the middle of its 52-week range of $13.60 to $17.65: 9.3% below the high, set on Nov 11, 2026 and 17.6% above the low.
Bambusa Therapeutics has posted a net loss over the last twelve months (EPS of -$1.73), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Bambusa Therapeutics
Company profileBambusa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops long-acting bispecific antibodies for the treatment of immunological and inflammatory disorders. The company develops BBT001 for Type 2 inflammatory dermatological conditions, including atopic dermatitis, chronic spontaneous urticaria, and prurigo nodularis. It also develops BBT002, a long-acting bispecific antibody for respiratory and other Type 2 inflammatory diseases.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Shanshan Xu M.B.A., M.D., Ph.D.
- Headquarters
- Boston, MA
- Employees
- 26
- IPO year
- 2026
- Website
- bambusatx.com
Bambusa Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ODTXOdyssey Therapeutics Inc. | 16.96 | -7.52% | $815.23M | vs BBTX |
| PRMEPrime Medicine Inc. | 3.55 | -7.55% | $791.62M | vs BBTX |
| MGTXMeiraGTx Holdings plc | 7.98 | -1.97% | $779.89M | vs BBTX |
| IMTXImmatics N.V. | 5.77 | -3.03% | $878.58M | vs BBTX |
| GLUEMonte Rosa Therapeutics Inc. | 8.64 | -3.03% | $738.29M | vs BBTX |
| AURAAura Biosciences Inc. | 6.87 | -1.58% | $714.99M | vs BBTX |
| SLDBSolid Biosciences Inc. | 6.25 | -2.95% | $697.57M | vs BBTX |
| ATTOAttovia Therapeutics Inc. | 15.10 | -3.08% | $690.26M | vs BBTX |
Indexes, lists and sector
Bambusa Therapeutics stock FAQ
What is Bambusa Therapeutics's stock price today?
BBTX last traded at $16.00 as of Nov 20, 4:00 PM EST, up 2.89% on the day. Prices are delayed at least 15 minutes.
Who is Bambusa Therapeutics's CEO?
Dr. Shanshan Xu M.B.A., M.D., Ph.D. is the chief executive officer of Bambusa Therapeutics Inc., which has about 26 employees.
What is the BBTX 52-week high?
The 52-week high for BBTX is $17.65 and the 52-week low is $13.60. The stock is currently 9.3% below its high.